Acknowledgements To conduct this meta-analysis, the first author (L.G.S.P) received a research scholarship granted by the Brazilian National Research Council (CNPq) under the protocol 134326/2024-5
No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia
declares having received honoraria from AstraZeneca, Bayer Yakuhin, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Novo Nordisk Pharma, Ono Pharmaceutical, Otsuka and Tsumura
Combining surgical approaches with the latest medications offers transformative results, but timing, nutrition, and mindset all play pivotal roles
Hepatic encephalopathy: a review